Trial summary
KATRINA is a multicentre, retrospective cohort study aiming to collect data related to patient and disease characteristics, treatment patterns and outcomes of early triple negative breast cancer in a routine clinical practice patient population, who have received pembrolizumab in the neoadjuvant setting via a medicine access program or reimbursed supply in Australia.
There is no direct involvement of patients in this study. The study is collecting data retrospectively from medical records. Patients will not be asked to complete any assessments for the study that is outside routine clinical practice. The total duration of the study is 5 years (June 2024 to June 2028), allowing for a median follow up period of 3.5 years.
Trial details
Short title
KATRINA
Diagnosis
Breast cancer
Type of treatment
Other
Phase
N/A
Who can participate
Clinical trials can have restrictive criteria of who can and can’t participate, talk to your healthcare provider if you are interested in this clinical trial.